Biologic Therapeutics Market Forecasts to 2030 – Global Analysis By Product (Gene Therapy, Cell Therapy, Vaccines, Antibody Therapeutics and Other Products), Type, Application and By Geography

Biologic Therapeutics Market Forecasts to 2030 – Global Analysis By Product (Gene Therapy, Cell Therapy, Vaccines, Antibody Therapeutics and Other Products), Type, Application and By Geography

According to Stratistics MRC, the Global Biologic Therapeutics Market is accounted for $457.56 billion in 2023 and is expected to reach $968.08 billion by 2030 growing at a CAGR of 11.3% during the forecast period. The pharmaceutical industry sector that concentrates on the development, production, and marketing of therapeutic medicines generated from biological sources is referred to as the biologic therapeutics market. These complex chemicals are created using living organisms or their parts, such as proteins, antibodies, nucleic acids, or cells. They are also referred to as biologics or biological pharmaceuticals.

According to World Health Organization, vaccines are one of the most powerful and cost-effective ways to reduce the global burden of disease and are estimated to save 2–3 million lives every year.

Market Dynamics

Driver

Increasing prevalence of age-related and chronic diseases and expanding pipeline of biologics

The need for efficient treatment alternatives is being driven by the increased prevalence of chronic diseases like cancer, autoimmune conditions, and metabolic diseases. Biologic medicines provide customized, targeted treatments that can address the underlying causes of many disorders, spurring market expansion. Additionally, the development of biologic medicines has received significant funding from the pharmaceutical and biotechnology industries. Biologic medication development, including recombinant proteins, cell and gene therapies, and monoclonal antibodies, is boosting the market and spurring innovation.

Restraint

High costs of development and production, manufacturing and supply chain management are quite complex

Complex procedures and high expenditures, such as those associated with research and development, clinical trials, and manufacturing facilities, are involved in the creation and production of biologic therapies. Particularly in healthcare systems with limited resources, these high costs may restrict the availability and affordability of biologic medications. However, due to their complicated nature, biologic pharmaceuticals need specialized production facilities and procedures. It can be difficult to ensure consistent quality, scaleability, and maintain a strong supply chain, which may have an impact on the accessibility and affordability of biologic treatments.

Opportunity

Biotechnology and genetic engineering advancements and favorable regulatory landscape

The potential for creating innovative biological therapies has increased as a result of ongoing developments in biotechnology, genetic engineering, and recombinant DNA technology. These technological developments make it possible to produce biological medications that are more sophisticated and specifically targeted, expanding the number of available treatments. Additionally, regulatory organizations have established precise rules and accelerated paths for the approval of biologic therapies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). These regulatory regimes offer a favorable environment for the creation, assessment, and marketing of biologic medicines.

Threat

High standards of regulation and concerns about immunogenicity and safety

Despite the existence of favorable regulatory frameworks, the complex and stringent approval procedures for biologic therapies. Extensive preclinical and clinical trials that must be conducted by companies to prove safety, efficacy, and quality can take a long time and cost a lot of funds. However, patients' immune responses to biological therapies may be induced, raising concerns regarding their safety and immunogenicity. The effectiveness and safety of the treatment may be impacted by these immunological reactions, which can range in severity. For biological treatments to be used effectively, it is crucial to provide effective monitoring and management of these problems.

Covid-19 Impact

The COVID-19 epidemic made the creation and distribution of efficient vaccinations essential. As a result, vaccine research and development significantly increased, utilizing biological platforms like mRNA and viral vector-based vaccines. The effective creation and application of COVID-19 vaccines highlighted the promise of biological treatments and emphasized the significance of the biotechnology sector in combating infectious diseases.

The blood products segment is expected to be the largest during the forecast period

Blood products segment commanded the largest share over the forecast period. Blood-derived products, including immunoglobulins, clotting factors, and plasma-derived proteins, which are used to treat a variety of blood illnesses and immunological deficiencies, are also considered to be part of biologic therapies. The use of these items is essential in the management of a number of blood diseases, immunological deficiencies, and other ailments.

The cell therapy segment is expected to have the highest CAGR during the forecast period

Cell therapy segment is estimated to witness lucrative growth over the projection period. Living cells are used in cell therapy to treat or cure diseases. It is a fast-developing area that seeks to replace, restore, or fix damaged or sick cells or tissues. Additionally, cell therapy has demonstrated potential in a number of therapeutic fields, including oncology, cardiovascular illness, neurodegenerative disorders, and autoimmune diseases.

Region with largest share

Asia Pacific is expected to hold largest share over the forecast period as the biological therapies industry experiences substantial development and innovation, the Asia-Pacific region is emerging as a vibrant and quickly changing hub. This region is connected to numerous nations with distinctive healthcare systems, making it a complex yet attractive market. Additionally, the region's growing need for biological treatments is being driven by the prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders.

Region with highest CAGR

Asia Pacific is estimated to hold highest CAGR. The availability of biological therapies has expanded as a result of an expanding middle-class population and rising healthcare costs. This has further propelled the market's growth, along with government policies to encourage the construction of healthcare infrastructure. Additionally, the Asia-Pacific region is experiencing a boom in research and development activity, with both domestic and foreign pharmaceutical firms making significant investments in the development of biologic drugs. A thriving biotechnology ecosystem has resulted in an outcome that draws in talent and encourages innovation. Governments in the area are also making efforts to simplify approval procedures, improving the simplicity of market access for biopharmaceutical firms.

Key players in the market

Some of the key players in Biologic Therapeutics Market include AbbVie Inc, Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc, Biocon Ltd., Celltrion Healthcare Co. Ltd., GlaxoSmithKline Plc, Merck and Co. Inc, Novartis AG, Pfizer Inc , Precision Biologics Inc and Samsung Electronics Co. Ltd.

Key Developments

In May 2022, Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, announceD the launch of its new CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities. The announcement was made at the World Federation of Hemophilia Congress taking place in Montreal

Products Covered
• Gene Therapy
• Cell Therapy
• Vaccines
• Antibody Therapeutics
• Other Products

Types Covered
• Allergenic Extracts
• Blood Products
• Human Cells and Tissues
• Protein
• Xenotransplantation Products
• Other Types

Applications Covered
• Autoimmune Diseases
• Infectious Diseases
• Cancer
• Other Applications

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements